Treatment-related adverse events (TRAEs) were seen in 80% of patients in the nivolumab-ipilimumab arm and 94% of those in the chemotherapy arm. Rates of grade 3-4 TRAEs were ... stomatitis (12% and <1 ...
Artelo Biosciences (NASDAQ:ARTL – Get Free Report)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $6.00 price ...